Liver-specific contrast media for MRI and CT experimental studies

Area of Science:

• Radiology and Medical Imaging
• Oncology
• Pharmacology

Background:

• Magnetic resonance imaging (MRI) and computed tomography (CT) are key modalities for liver imaging.
• Contrast media (CM) enhance sensitivity for diagnosing focal liver lesions.
• Non-specific extracellular CM offer suboptimal contrast due to rapid diffusion into both normal and tumorous tissues.

Purpose of the Study:

• To evaluate the imaging efficacy of experimental liver-specific contrast agents.
• To determine if liver-specific CM enhance normal liver tissue.
• To assess if enhanced normal liver tissue improves contrast with tumorous tissue and increases tumor detection rates.

Main Methods:

• Animal models (rabbits with VX2-carcinoma liver tumors) were used to test liver-specific CM (Mn-DPDP for MRI; IEEC-particles and iodixanol-liposomes for CT).
• Evaluated signal alteration in normal liver tissue and contrast-to-noise ratios.
• Compared tumor detection rates with non-enhanced, contrast-enhanced MRI, and CT using specific and non-specific CM.

Main Results:

• All tested liver-specific CM significantly altered the signal in normal liver tissue.
• Liver-specific CM (Mn-DPDP, IEEC-particles, iodixanol-liposomes) significantly increased contrast between normal liver and tumorous tissue.
• Tumor detection frequency was significantly higher with liver-specific CM in both MRI and CT compared to precontrast values.
• Non-specific extracellular CM (iohexol) in CT showed no improvement in contrast or tumor detection.

Conclusions:

• Liver-specific contrast agents enhance normal liver tissue contrast, leading to higher tumor detection rates in MRI and CT.
• MRI and CT demonstrate comparable potential for liver tumor detection when using appropriate contrast agents.
• Liver-specific CM are user-friendly, allowing intravenous administration and long imaging windows.